Skip to content

Research at St Andrews

Modular cell-based platform for high throughput identification of compounds that inhibit a viral interferon antagonist of choice

Research output: Research - peer-reviewArticle


Open Access permissions



Andri Vasou, Christina Paulus, Janina Narloch, Zoe O. Gage, Marie-Anne Rameix-Welti, Jean-François Eléouët, Michael Nevels, Richard E. Randall, Catherine S. Adamson

School/Research organisations


Viral interferon (IFN) antagonists are a diverse class of viral proteins that counteract the host IFN response, which is important for controlling viral infections. Viral IFN antagonists are often multifunctional proteins that perform vital roles in virus replication beyond IFN antagonism. The critical importance of viral IFN antagonists is highlighted by the fact that almost all viruses encode one of these proteins. Inhibition of viral IFN antagonists has the potential to exert pleiotropic antiviral effects and thus this important protein class represents a diverse plethora of novel therapeutic targets. To exploit this, we have successfully developed and executed a novel modular cell-based platform that facilitates the safe and rapid screening for inhibitors of a viral IFN antagonist of choice. The platform is based on two reporter cell-lines that provide a simple method to detect activation of IFN induction or signaling via an eGFP gene placed under the control of the IFNβ or an ISRE-containing promoter, respectively. Expression of a target IFN antagonist in the appropriate reporter cell-line will block the IFN response and hence eGFP expression. We hypothesized that addition of a compound that inhibits IFN antagonist function will release the block imposed on the IFN response and hence restore eGFP expression, providing a measurable parameter for high throughput screening (HTS). We demonstrate assay proof-of-concept by (i) exploiting hepatitis C virus (HCV) protease inhibitors to inhibit NS3-4A's capacity to block IFN induction and (ii) successfully executing two HTS targeting viral IFN antagonists that block IFN signaling; NS2 and IE1 from human respiratory syncytial virus (RSV) and cytomegalovirus (CMV) respectively, two clinically important viruses for which vaccine development has thus far been unsuccessful and new antivirals are required. Both screens performed robustly and Z′ Factor scores of >0.6 were achieved. We identified (i) four hit compounds that specifically inhibit RSV NS2's ability to block IFN signaling by mediating STAT2 degradation and exhibit modest antiviral activity and (ii) two hit compounds that interfere with IE1 transcription and significantly impair CMV replication. Overall, we demonstrate assay proof-of-concept as we target viral IFN antagonists from unrelated viruses and demonstrate its suitability for HTS.


Original languageEnglish
Pages (from-to)79-92
JournalAntiviral Research
Early online date14 Oct 2017
StatePublished - Feb 2018

    Research areas

  • Viral interferon (IFN) antagonists, Antivirals, Human Respiratory Syncytial Virus (RSV), Human Cytomegalovirus (CMV), High-throughput screening (HTS), Signal transducer and activator of transcription 2 (STAT2)

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. ARID3B: a novel regulator of the Kaposi’s sarcoma-associated herpesvirus lytic cycle

    Wood, J., Boyne, J., Paulus, C., Jackson, B., Nevels, M. M., Whitehouse, A. & Hughes, D. J. Oct 2016 In : Journal of Virology. 90, 20, p. 9543-9555

    Research output: Research - peer-reviewArticle

  2. Identification of novel inhibitors of the type I interferon induction pathway using cell-based high-throughput screening

    Gage, Z. O., Vasou, A., Gray, D., Randall, R. E. & Adamson, C. S. Oct 2016 In : Journal of Biomolecular Screening. 21, 9, p. 978-988 11 p.

    Research output: Research - peer-reviewArticle

  3. Human cytomegalovirus immediate-early 1 protein rewires upstream STAT3 to downstream STAT1 signaling switching an IL6-type to an IFNγ-like response

    Harwardt, T., Lukas, S., Zenger, M., Reitberger, T., Danzer, D., Übner, T., Munday, D. C., Nevels, M. & Paulus, C. 7 Jul 2016 In : PLoS Pathogens. 12, 7, 39 p., e1005748

    Research output: Research - peer-reviewArticle

  4. The proteome of human cytomegalovirus virions and dense bodies is conserved across different strains

    Büscher, N., Paulus, C., Nevels, M., Tenzer, S. & Plachter, B. Jun 2015 In : Medical Microbiology and Immunology. 204, 3, p. 285-293 9 p.

    Research output: Research - peer-reviewArticle

  5. Inhibitors of the interferon response enhance virus replication in vitro.

    Stewart, C. E., Randall, R. E. & Adamson, C. S. 12 Nov 2014 In : PLoS One. 9, 11, 8 p., e112014

    Research output: Research - peer-reviewArticle

Related by journal

  1. Novel approaches to inhibiting HIV-1 replication

    Adamson, C. S. & Freed, E. O. 2010 In : Antiviral Research. 85, 1, p. 119-141

    Research output: Research - peer-reviewArticle

  2. Characteristics of arbidol-resistant mutants of influenza virus: Implications for the mechanism of anti-influenza action of arbidol

    Leneva, I. A., Russell, R. J. M., Boriskin, Y. S. & Hay, A. J. Feb 2009 In : Antiviral Research. 81, p. 132-140 9 p.

    Research output: Research - peer-reviewArticle

ID: 251360897